AMPA Potentiation as a Treatment Option for Alzheimer’s Disease
Alpha-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA) receptor modulators, although still in their infancy from a therapeutic standpoint, have the potential to correct the deficits associated with cognitive disorders such as Alzheimer’s disease (AD). This chapter reviews the AMPA receptor’s role in long-term potentiation and thus in learning and memory, and describes the AMPA potentiators currently under development.
KeywordsAttention Deficit Hyperactivity Disorder Glutamate Receptor Attention Deficit Hyperactivity Disorder Synaptic Strength Nootropic Drug
Unable to display preview. Download preview PDF.
- 8.Beattie, E.C. et al.: Regulation of AMPA receptor endocytosis by a signaling mechanism shared with LTD. Nat Neurosci 2000; 3: 12.Google Scholar
- 12.Zivkovic. I. et al.: 7-Chloro-3-methyl-3–4-dihydro-2H-1,2,4 benzothiadiazine S,S-dioxide (IDRA 21): a benzothiadiazine derivative that enhances cognition by attenuating DL- amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoic acid (AMPA) receptor desensitization. J Pharmacol Exp Ther 1995; 272: 300–309.PubMedGoogle Scholar
- 16.Petkov, V.D. et al.: Age-related differences in memory and in the memory effects of nootropic drugs. Acta Physiol Pharmacol Bulgarica 1990; 16: 28–36.Google Scholar
- 20.Szabadits, P.; Mike, A.; Vizi, E.S.: Modulation of agonist-evoked responses of hippocampal AMPA receptors by IDRA 21 and cyclothiazide (abstr 143.8). World Congr Pharmacol 2002.Google Scholar
- 27.Urbanics, R.: Neurodegenerative Drug Discovery and Development New Directions. IDDB Meeting Report, July 18–19, 2001, London, UK.Google Scholar